Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Peripheral T-cell Lymphoma
• Small Lymphocytic Lymphoma
• T-cell Lymphoma

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-05